GeneDx Holdings (WGS) Cash from Financing Activities (2020 - 2026)

GeneDx Holdings (WGS) has reported Cash from Financing Activities for 7 consecutive years, with $38.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 181.31% year-over-year to $38.6 million; the TTM figure through Mar 2026 stood at $72.9 million (up 25.0% YoY), while the FY2025 annual figure was $48.0 million, up 8.75% from the prior year.
• Cash from Financing Activities rose to $38.6 million in Q1 2026 per WGS's latest filing, from $23.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $198.1 million in Q2 2022 and bottomed at -$911000.0 in Q3 2023.
• Historically, Cash from Financing Activities has averaged $30.3 million across 5 years, with a median of $10.8 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 83011.25% — and 2024, when it plunged 105.29%.
• GeneDx Holdings' Cash from Financing Activities stood at $65000.0 in 2022, then soared by 72366.15% to $47.1 million in 2023, then tumbled by 34.14% to $31.0 million in 2024, then fell by 25.24% to $23.2 million in 2025, then surged by 66.39% to $38.6 million in 2026.
• Business Quant data shows WGS's Cash from Financing Activities at $38.6 million in Q1 2026, $23.2 million in Q4 2025, and $10.8 million in Q3 2025.